Cardiopulmonary involvement in Puumala hantavirus infection

BMC Infectious Diseases

Table 1 Clinical findings and laboratory results in acute phase and at follow-up in Puumala hantavirus infection

	Acute phase	Follow-up^a
Number of patients	27	26
Clinical findings
Hypotension (≤90 mmHg)	9 (33%)	0
Respiratory symptoms	18 (67%)	6 (23%)
Dyspnoea	14 (52%)	6 (23%)
Dry cough	10 (37%)	0
Oxygen treated	9 (33%)	0
Acute renal failure^b	17 (63%)	0
Oliguria (<400 mL/24 hours)	3 (11%)	0
Laboratory results
Leukocyte count max (3.5-8.8 10⁹/L)	8.8 (7.0-12.3)	6.4 (5.3-8.1)
CRP max (<3 mg/L)	115 (47–166)	<3 (<3- < 3)
Platelet count min (145–387 10⁹/L)	66 (51–90)	249 (208–304)
D-dimer max (<0.2 mg/L)	1.1 (0.7-1.7)	0.1 (0.1-0.2)
Creatinine max (<105 μmol/L)	177 (121–304)	69 (57–92)
Lactate dehydrogenase max (<3.4 μkat/L)	4.9 (4.3-6.4)	3.1 (2.8-3.5)
Albumin min (36–45 g/L)	28 (22–30)	45 (42–47)
Cardiac biomarkers
NT-proBNP inclusion (<150 ng/L)	646 (222–1568)	-
NT-proBNP max (<150 ng/L)	1768 (585–5067)	62 (32–130)
hs-cTnT max (<15 ng/L)	7 (0–16)	0 (0–7)

^aLaboratory parameters normalised at follow-up (P < 0.001 for all, Wilcoxon signed-ranks test), compared to the acute phase, ^b Defined as creatinine concentration >150 μmol L^-1. CRP, C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; max, maximum; min, minimum; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Clinical findings are presented as number of patients (%) with the respective finding, while laboratory parameters are expressed as median (25^th-75^th percentiles). Reference values (decision level for heart failure or myocardial injury for NT-ProBNP and hs-cTnT respectively) are presented in parenthesis.

ISSN: 1471-2334